Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Neurogene Inc.
Headquarters: New York, NY, United States of America
Website: https://www.neurogene.com/
Year Founded: 2018
Status: Public
Industry Sector: HealthTechnology
CEO: Rachel L. McMinn, PhD
Number Of Employees: 107
Enterprise Value: $101,606,495
PE Ratio: -2.1
Exchange/Ticker 1: NASDAQ:NGNE
Exchange/Ticker 2: N/A
Latest Market Cap: $144,369,200
BioCentury | Nov 27, 2024
Product Development
Biohaven’s Phase III SMA miss: was it the target or the trial design?
BioCentury’s latest Clinical Report also analyzes results from Alector, NewAmsterdam and Pyxis that led shares to slip, and more
BioCentury | Nov 13, 2024
Product Development
Adverse event casts shadow over Neurogene’s Rett syndrome readout
BioCentury’s Clinical Report also analyzes data from Syndax and Gan & Lee, plus pipeline updates from Sarepta, Tango and RAPT
BioCentury | Nov 8, 2024
Finance
Neurogene draws $200M PIPE ahead of next week’s Rett syndrome data
In BioCentury’s Finance Report: Travere’s follow-on, CrossBridge’s seed round among few fundings during quiet election week
BioCentury | Jan 17, 2024
Management Tracks
CEO departures at Aclaris and Vaxart
Plus: David Pyrce named CEO at Cognigenics, and updates from NextPoint, Hookipa, NeoImmuneTech, Neurogene, Paratek and Aspen
BioCentury | Jul 28, 2023
Deals
Biotech reverse mergers growing amid improving market conditions
Are 2023’s reverse mergers another sign of an improving biotech environment?
BioCentury | Jul 18, 2023
Finance
July 18 Quick Takes: Pfizer, Flagship to launch up to 10 single-asset programs
Plus: J&J joins the IRA litigation club and updates from Novartis, Neurogene and Renibus
BioCentury | Dec 17, 2020
Finance
Dec. 16 Quick Takes: Neurogene raises $115M while BioAtla sees first-day pop; plus fundings for Atsena, MinervaX, Vivace, Arvinas
Megaround for gene therapy play NeurogeneNeurogene Inc. raised $115 million in a series B round led by EcoR1 Capital, with participation by existing investors Redmile Group, Samsara BioCapital and
BioCentury | Jul 18, 2020
Management Tracks
Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more
BioCentury | Sep 27, 2019
Company News
Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne
BioCentury | Apr 4, 2019
Translation in Brief
Promoting AAV vectors to safety
Why promoters, other genetic cargo in AAV vectors should be tested for toxicity
Items per page:
1 - 10 of 15